These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 35737301)
1. Potentials of autophagy enhancing natural products in the treatment of Parkinson disease. Olubodun-Obadun TG; Ishola IO; Adeyemi OO Drug Metab Pers Ther; 2021 Aug; 37(2):99-110. PubMed ID: 35737301 [TBL] [Abstract][Full Text] [Related]
2. Potentials of autophagy enhancing natural products in the treatment of Parkinson disease. Olubodun-Obadun TG; Ishola IO; Adeyemi OO Drug Metab Pers Ther; 2021 Aug; ():. PubMed ID: 34391219 [TBL] [Abstract][Full Text] [Related]
3. The vicious cycle between α-synuclein aggregation and autophagic-lysosomal dysfunction. Bellomo G; Paciotti S; Gatticchi L; Parnetti L Mov Disord; 2020 Jan; 35(1):34-44. PubMed ID: 31729779 [TBL] [Abstract][Full Text] [Related]
4. Age-dependent accumulation of oligomeric SNCA/α-synuclein from impaired degradation in mutant LRRK2 knockin mouse model of Parkinson disease: role for therapeutic activation of chaperone-mediated autophagy (CMA). Ho PW; Leung CT; Liu H; Pang SY; Lam CS; Xian J; Li L; Kung MH; Ramsden DB; Ho SL Autophagy; 2020 Feb; 16(2):347-370. PubMed ID: 30983487 [TBL] [Abstract][Full Text] [Related]
5. A Cleaning Crew: The Pursuit of Autophagy in Parkinson's Disease. Parekh P; Sharma N; Gadepalli A; Shahane A; Sharma M; Khairnar A ACS Chem Neurosci; 2019 Sep; 10(9):3914-3926. PubMed ID: 31385687 [TBL] [Abstract][Full Text] [Related]
6. Acidic nanoparticles protect against α-synuclein-induced neurodegeneration through the restoration of lysosomal function. Arotcarena ML; Soria FN; Cunha A; Doudnikoff E; Prévot G; Daniel J; Blanchard-Desce M; Barthélémy P; Bezard E; Crauste-Manciet S; Dehay B Aging Cell; 2022 Apr; 21(4):e13584. PubMed ID: 35318803 [TBL] [Abstract][Full Text] [Related]
8. Are Lysosomes Potential Therapeutic Targets for Parkinson's Disease? Petese A; Cesaroni V; Cerri S; Blandini F CNS Neurol Disord Drug Targets; 2022; 21(8):642-655. PubMed ID: 34370650 [TBL] [Abstract][Full Text] [Related]
9. TMEM175 deficiency impairs lysosomal and mitochondrial function and increases α-synuclein aggregation. Jinn S; Drolet RE; Cramer PE; Wong AH; Toolan DM; Gretzula CA; Voleti B; Vassileva G; Disa J; Tadin-Strapps M; Stone DJ Proc Natl Acad Sci U S A; 2017 Feb; 114(9):2389-2394. PubMed ID: 28193887 [TBL] [Abstract][Full Text] [Related]
10. Ferritinophagy and α-Synuclein: Pharmacological Targeting of Autophagy to Restore Iron Regulation in Parkinson's Disease. Boag MK; Roberts A; Uversky VN; Ma L; Richardson DR; Pountney DL Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216492 [TBL] [Abstract][Full Text] [Related]
11. Autophagy and Alpha-Synuclein: Relevance to Parkinson's Disease and Related Synucleopathies. Xilouri M; Brekk OR; Stefanis L Mov Disord; 2016 Feb; 31(2):178-92. PubMed ID: 26813776 [TBL] [Abstract][Full Text] [Related]
12. The Overcrowded Crossroads: Mitochondria, Alpha-Synuclein, and the Endo-Lysosomal System Interaction in Parkinson's Disease. Lin KJ; Lin KL; Chen SD; Liou CW; Chuang YC; Lin HY; Lin TK Int J Mol Sci; 2019 Oct; 20(21):. PubMed ID: 31731450 [TBL] [Abstract][Full Text] [Related]
13. A new perspective in Parkinson's disease, chaperone-mediated autophagy. Li B; Zhang Y; Yuan Y; Chen N Parkinsonism Relat Disord; 2011 May; 17(4):231-5. PubMed ID: 21215675 [TBL] [Abstract][Full Text] [Related]
14. Neurotrophic factors for disease-modifying treatments of Parkinson's disease: gaps between basic science and clinical studies. Chmielarz P; Saarma M Pharmacol Rep; 2020 Oct; 72(5):1195-1217. PubMed ID: 32700249 [TBL] [Abstract][Full Text] [Related]
15. Lysosomal functions and dysfunctions: Molecular and cellular mechanisms underlying Gaucher disease and its association with Parkinson disease. Horowitz M; Braunstein H; Zimran A; Revel-Vilk S; Goker-Alpan O Adv Drug Deliv Rev; 2022 Aug; 187():114402. PubMed ID: 35764179 [TBL] [Abstract][Full Text] [Related]
16. The Interplay between Alpha-Synuclein Clearance and Spreading. Lopes da Fonseca T; Villar-Piqué A; Outeiro TF Biomolecules; 2015 Apr; 5(2):435-71. PubMed ID: 25874605 [TBL] [Abstract][Full Text] [Related]
17. Alpha-synuclein's degradation in vivo: opening a new (cranial) window on the roles of degradation pathways in Parkinson disease. Ebrahimi-Fakhari D; McLean PJ; Unni VK Autophagy; 2012 Feb; 8(2):281-3. PubMed ID: 22301995 [TBL] [Abstract][Full Text] [Related]
18. Targeting α-Synuclein in Parkinson's Disease: Progress Towards the Development of Disease-Modifying Therapeutics. Savitt D; Jankovic J Drugs; 2019 Jun; 79(8):797-810. PubMed ID: 30982161 [TBL] [Abstract][Full Text] [Related]
19. Therapeutic potentials of plant iridoids in Alzheimer's and Parkinson's diseases: A review. Dinda B; Dinda M; Kulsi G; Chakraborty A; Dinda S Eur J Med Chem; 2019 May; 169():185-199. PubMed ID: 30877973 [TBL] [Abstract][Full Text] [Related]
20. The Parkinson disease protein α-synuclein inhibits autophagy. Winslow AR; Rubinsztein DC Autophagy; 2011 Apr; 7(4):429-31. PubMed ID: 21157184 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]